Mereo BioPharma Group PLC ADR (MREO)

Mereo BioPharma Group PLC ADR (MREO) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $55.9M; returns 1 day -2.0%, 1 week -7.0%, 1 year -85.9%.

Mereo BioPharma Group PLC is a biopharmaceutical company based in the United Kingdom that focuses on developing and commercializing therapeutics for rare diseases and oncology. The company's pipeline includes product candidates such as Setrusumab for osteogenesis imperfecta (OI) and Alvelestat for Alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

Groups MREO belongs to

• Biotechnology
• Biopharmaceutical
• United Kingdom Companies
• Rare Diseases
• Clinical Stage Biotech
• Healthcare
• Clinical Stage
• Life Sciences
• Oncology

MREO financial model: income statement, cash flow and balance sheet